U.S. Markets closed

Novartis Expects FDA and EMA Approvals for Aimovig in 2018

Margaret Patrick
Novartis Expects FDA and EMA Approvals for Aimovig in 2018

Novartis: What Are the Major Growth Drivers for 2018? Aimovig, which is Novartis’s (NVS) investigational migraine prophylaxis therapy, is currently under review by the FDA and the European Medicines Agency (or EMA). More than 10.0% of the adults in the world suffer from migraine.